EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders

Porkizhi Arjunan, Durga Kathirvelu, Gokulnath Mahalingam, Ashish Kumar Goel, Uday George Zacharaiah, Alok Srivastava, Srujan Marepally

Acta Pharmaceutica Sinica B · 2024-07 · 14 (7) · 2885-2900

DOI: 10.1016/j.apsb.2024.04.015 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2024-07. Verfasst von Porkizhi Arjunan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Stem Cell Research (A Unit of inStem, Bengaluru), Christian Medical College Campus, Bagayam, Vellore 632002, Tamil Nadu, India. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India, Christian Medical College Vellore.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inherited genetic disorders of the liver pose a significant public health burden. Liver transplantation is often limited by the availability of donor livers and the exorbitant costs of immunosuppressive therapy. To overcome these limitations, nucleic acid therapy provides a hopeful alternative that enables gene repair, gene supplementation, and gene silencing with suitable vectors. Though viral vectors are the most efficient and preferred for gene therapy, pre-existing immunity debilitating immune responses limit their use. As a potential alternative, lipid nanoparticle-mediated vectors are being explored to deliver multiple nucleic acid forms, including pDNA, mRNA, siRNA, and proteins. Herein, we discuss the broader applications of lipid nanoparticles, from protein replacement therapy to restoring the disease mechanism through nucleic acid delivery and gene editing, as well as multiple preclinical and clinical studies as a potential alternative to liver transplantation.

Schlagwörter

Stichwörter der Autor:innen

ASOClinical trialsGene editingGene therapyLipid nanoparticleLiver disordersNucleic acid deliverymRNApDNAsiRNA

Autor:innen und Institutionen

  • Center for Stem Cell Research (A Unit of inStem, Bengaluru), Christian Medical College Campus, Bagayam, Vellore 632002, Tamil Nadu, India.
  • Manipal academy for higher education, Mangalore 576104, Karnataka, India.
  • Department of Hepatology, Christian Medical College & Hospital, Vellore 632004, Tamil Nadu, India.
  • Department of Hematology, Christian Medical College & Hospital, Vellore 632004, Tamil Nadu, India.

Förderung

  • Department of Biotechnology, Ministry of Science and Technology, India
  • Christian Medical College Vellore

Zitieren

APA

Arjunan, P., Kathirvelu, D., Mahalingam, G., Goel, A. K., Zacharaiah, U. G., Srivastava, A., & Marepally, S. (2024). Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders. Acta Pharmaceutica Sinica B, 14(7), 2885-2900. https://doi.org/10.1016/j.apsb.2024.04.015

Vancouver

Arjunan P, Kathirvelu D, Mahalingam G, Goel AK, Zacharaiah UG, Srivastava A, et al. Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders. Acta Pharmaceutica Sinica B. 2024;14(7):2885-2900. doi:10.1016/j.apsb.2024.04.015

BibTeX
@article{Arjunan2024,
  author = {Arjunan, Porkizhi and Kathirvelu, Durga and Mahalingam, Gokulnath and Goel, Ashish Kumar and Zacharaiah, Uday George and Srivastava, Alok and Marepally, Srujan},
  title = {Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2024},
  volume = {14},
  number = {7},
  pages = {2885--2900},
  doi = {10.1016/j.apsb.2024.04.015}
}
Kostenlos starten →